Explore

Trendline Trendline
Viridian Therapeutics Launches Public Offerings to Raise Funds for Autoimmune and Rare Disease Treatments

Viridian Therapeutics Launches Public Offerings to Raise Funds for Autoimmune and Rare Disease Treatments

Viridian Therapeutics Launches Public Offerings to Raise Funds for Autoimmune and Rare Disease Treatments
Trendline Trendline
Viridian Therapeutics Launches Public Offerings to Fund Research and Development

Viridian Therapeutics Launches Public Offerings to Fund Research and Development

Viridian Therapeutics Launches Public Offerings to Fund Research and Development
Trendline Trendline
Zura Bio Grants Inducement Awards to New Employees, Expanding Workforce

Zura Bio Grants Inducement Awards to New Employees, Expanding Workforce

Zura Bio Grants Inducement Awards to New Employees, Expanding Workforce
Trendline Trendline
EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding

EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding

EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding
Trendline Trendline
Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones

Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones

Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones
Trendline Trendline
DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress
Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Trendline Trendline
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark
Trendline Trendline
Zura Bio Announces Inducement Grants to New Employees Under Nasdaq Rule

Zura Bio Announces Inducement Grants to New Employees Under Nasdaq Rule

Zura Bio Announces Inducement Grants to New Employees Under Nasdaq Rule
Trendline Trendline
Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease